You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 7, 2025

Investigational Drug Information for ABBV-951


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug ABBV-951?

ABBV-951 is an investigational drug.

There have been 7 clinical trials for ABBV-951. The most recent clinical trial was a Phase 3 trial, which was initiated on June 8th 2020.

The most common disease conditions in clinical trials are Parkinson Disease and [disabled in preview]. The leading clinical trial sponsors are AbbVie and [disabled in preview].

There are six US patents protecting this investigational drug and three hundred and three international patents.

Recent Clinical Trials for ABBV-951
TitleSponsorPhase
Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's DiseaseAbbViePhase 1
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's DiseaseAbbViePhase 3
Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's DiseaseAbbViePhase 3

See all ABBV-951 clinical trials

Clinical Trial Summary for ABBV-951

Top disease conditions for ABBV-951
Top clinical trial sponsors for ABBV-951

See all ABBV-951 clinical trials

US Patents for ABBV-951

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ABBV-951 ⤷  Free Trial Carbidopa and L-dopa prodrugs and methods of use AbbVie Inc ⤷  Free Trial
ABBV-951 ⤷  Free Trial Carbidopa prodrug AbbVie Inc ⤷  Free Trial
ABBV-951 ⤷  Free Trial Topical with static photobiological functionality Maple Ridge Group, LLC (New York, NY) ⤷  Free Trial
ABBV-951 ⤷  Free Trial Simple coacervates and methods of use thereof University of Utah Research Foundation UURF, University of Utah ⤷  Free Trial
ABBV-951 ⤷  Free Trial Carbidopa and L-dopa prodrugs and methods of use AbbVie Inc ⤷  Free Trial
ABBV-951 ⤷  Free Trial Simple coacervates and methods of use thereof University of Utah Research Foundation UURF ⤷  Free Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for ABBV-951

Drugname Country Document Number Estimated Expiration Related US Patent
ABBV-951 Argentina AR102389 2034-10-21 ⤷  Free Trial
ABBV-951 Australia AU2015335941 2034-10-21 ⤷  Free Trial
ABBV-951 Australia AU2021201414 2034-10-21 ⤷  Free Trial
ABBV-951 Brazil BR112017008198 2034-10-21 ⤷  Free Trial
ABBV-951 Canada CA2965379 2034-10-21 ⤷  Free Trial
ABBV-951 China CN107206013 2034-10-21 ⤷  Free Trial
ABBV-951 China CN111362980 2034-10-21 ⤷  Free Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Transforming Parkinson's Treatment: The Journey of ABBV-951

Introduction to ABBV-951

ABBV-951, developed by AbbVie, is an investigational drug designed to treat motor fluctuations in patients with advanced Parkinson's disease. This innovative therapy involves a combination of foscarbidopa and foslevodopa, prodrugs of carbidopa and levodopa, delivered continuously under the skin via a subcutaneous pump[5].

The Need for Advanced Parkinson's Treatments

Parkinson's disease is a progressive and chronic neurological disorder characterized by the loss of dopamine-producing brain cells, leading to symptoms such as tremor, muscle rigidity, slowness of movement, and difficulty with balance. Current treatments, including oral carbidopa and levodopa, often have limitations, such as variable absorption and the need for frequent dosing. ABBV-951 aims to address these issues by providing a more consistent and convenient delivery method[5].

Mechanism of Action

ABBV-951 works by delivering foscarbidopa and foslevodopa continuously under the skin, which then convert into carbidopa and levodopa in the body. This approach targets dopamine receptors, potentially improving motor fluctuations in advanced Parkinson's disease patients. Unlike oral formulations, this subcutaneous delivery method offers the potential for more stable and predictable drug levels, enhancing the management of Parkinson's symptoms[5].

Clinical Trials and Development

ABBV-951 has undergone several clinical trials, including the Phase III M15-736 study, which formed the basis of its New Drug Application (NDA) submission to the FDA. These trials have focused on evaluating the safety, tolerability, and efficacy of ABBV-951 in patients with advanced Parkinson's disease. An ongoing open-label extension study (H-52937) is further assessing the long-term safety and pharmacokinetics of ABBV-951[4].

Regulatory Challenges

Despite its promising clinical data, ABBV-951 has faced regulatory hurdles. The FDA has issued Complete Response Letters (CRLs) twice, most recently due to observations from an inspection of a third-party manufacturer involved in the drug application. These issues did not pertain to the safety, efficacy, or labeling of ABBV-951 itself but rather to the manufacturing process. AbbVie remains committed to addressing these concerns and working with the FDA to bring ABBV-951 to market[1].

Market Potential and Forecast

Market forecasts indicate significant sales potential for ABBV-951 between 2024 and 2032, driven by the high unmet need in Parkinson's disease therapy. The report from ResearchAndMarkets.com highlights that the market scenario for Parkinson's disease is set to change due to extensive research and increased global healthcare spending. ABBV-951 is expected to play a crucial role in this evolving therapeutic landscape, potentially reaching peak sales of $1 billion to $2 billion[2][5].

Competitive Landscape

ABBV-951 is not alone in the race to improve Parkinson's disease treatments. Other therapies, such as Mitsubishi Tanabe Pharma's ND-0612, which also involves continuous subcutaneous infusion of liquid levodopa and carbidopa, are in development. ND-0612 recently faced an FDA rejection as well, indicating that the regulatory path for these innovative treatments is challenging. Additionally, Supernus's SPN-830, another infusion pump-based therapy, has faced multiple FDA rejections related to product quality and the infusion device[1].

Impact on Parkinson's Disease Treatment

The introduction of ABBV-951 could significantly alter the treatment scenario for Parkinson's disease. Its novel subcutaneous delivery mechanism offers the potential for improved motor function and a better quality of life for patients. This therapy aligns with the broader trend of developing more convenient and effective treatments for chronic neurological disorders[2].

Patient Benefits

For patients with advanced Parkinson's disease, ABBV-951 promises several benefits:

  • Continuous Delivery: Unlike oral medications that require frequent dosing, ABBV-951 provides a continuous flow of medication, potentially reducing the variability in drug levels.
  • Convenience: The subcutaneous pump offers a more convenient option compared to the oral gel formulation of Duopa, which requires administration through a stomach tube.
  • Improved Motor Function: By maintaining stable drug levels, ABBV-951 could improve motor function and reduce the severity of Parkinson's symptoms[5].

Industry Expert Insights

Industry experts and analysts have highlighted the potential of ABBV-951. For example, analysts at Evercore ISI have noted that ABBV-951 could be one of AbbVie’s biggest new product launches in the coming years, with potential sales exceeding $2 billion[1].

Future Outlook

Despite the current regulatory setbacks, AbbVie remains committed to bringing ABBV-951 to market. The company is working closely with the FDA to address the concerns raised and is not required to conduct additional efficacy or safety trials. With its strong pipeline and ongoing research, AbbVie is well-positioned to drive innovation in the treatment of Parkinson's disease and other neurological disorders[1][3].

Key Takeaways

  • Innovative Delivery: ABBV-951 offers a novel subcutaneous delivery method for treating advanced Parkinson's disease.
  • Regulatory Challenges: The drug has faced FDA rejections due to manufacturing issues, not related to its safety or efficacy.
  • Market Potential: Significant sales potential is forecasted between 2024 and 2032.
  • Competitive Landscape: ABBV-951 faces competition from other emerging therapies but remains a promising candidate.
  • Patient Benefits: Continuous delivery, convenience, and potential improvement in motor function are key benefits.

FAQs

What is ABBV-951 and how does it work?

ABBV-951 is an investigational drug containing foscarbidopa and foslevodopa, prodrugs of carbidopa and levodopa, delivered continuously under the skin via a subcutaneous pump to treat motor fluctuations in advanced Parkinson's disease.

Why has ABBV-951 been rejected by the FDA?

ABBV-951 has been rejected twice by the FDA, with the most recent rejection due to observations from an inspection of a third-party manufacturer involved in the drug application, not related to the safety, efficacy, or labeling of ABBV-951 itself.

What are the potential benefits of ABBV-951 for Parkinson's patients?

The potential benefits include continuous delivery of medication, convenience compared to current treatments, and improved motor function by maintaining stable drug levels.

How does ABBV-951 compare to other Parkinson's treatments?

ABBV-951 offers a more convenient and potentially more effective delivery method compared to oral formulations like Duopa and faces competition from other emerging therapies such as ND-0612.

What is the market forecast for ABBV-951?

Market forecasts suggest significant sales potential between 2024 and 2032, with potential peak sales ranging from $1 billion to $2 billion.

Sources

  1. FiercePharma: "AbbVie's Duopa successor in Parkinson's rejected for 2nd time"
  2. BusinessWire: "ABBV-951 in Parkinson's Disease Forecasts and Impacts to 2032"
  3. Nasdaq: "Should You Buy AbbVie Stock After Recent Parkinson's Study Success"
  4. Baylor College of Medicine: "An extension of studies to evaluate Abbv-951 in subjects with advanced Parkinson's disease"
  5. GlobeNewswire: "ABBV-951 for Parkinson's Disease: An Investigational Drug Containing Foslevodopa/Foscarbidopa Being Developed by AbbVie"

More… ↓

⤷  Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.